[Helicobacter pylori infection and gastric MALT lymphoma: present-day approaches to research and treatment].
Novik
A A
AA
Denisov
N L
NL
Gershanovich
M L
ML
Pozharisskiĭ
K M
KM
Gorodokin
I  V
I
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002908:Chronic Disease; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005756:Gastritis / Q000150:complications / Q000209:etiology; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics / Q000473:pathology / Q000601:surgery; D008967:Molecular Biology; D015337:Multicenter Studies as Topic; D009154:Mutation; D010641:Phenotype; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012106:Research; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology / Q000601:surgery; D014750:Vincristine / Q000627:therapeutic use
D018906:Antineoplastic Agents, Alkylating; D002699:Chlorambucil; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone